Viral Gandhi, MD
Pulmonary Disease · Albuquerque, NMNPI 1811245970
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 50.1% of the total. Reporting peaked in 2024 at $8,537 and has fallen 89.6% since, to $887 in 2025. Among pulmonary disease clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $47.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$1K
- Pulmonx Corporation$1K
- GSK$952
- Boehringer Ingelheim$573
- Grifols USA, LLC$515
- plus $3K from 33 others
What the payments were for
- Travel & lodging$3,74326%
- Food & beverage$6,62846%
- Education$4,08728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 25 | $7,240 |
| AstraZeneca(2 entities) | 60 | $1,284 |
| Pulmonx Corporation | 8 | $1,250 |
| GSK | 62 | $952 |
| Boehringer Ingelheim | 20 | $573 |
| Grifols USA, LLC | 18 | $515 |
| Mylan Specialty L.p. | 13 | $324 |
| Regeneron Healthcare Solutions, Inc. | 12 | $294 |
| AbbVie(2 entities) | 9 | $166 |
| United Therapeutics Corporation | 3 | $157 |
| Abiomed | 1 | $149 |
| Genentech USA, Inc. | 13 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $141 |
| Sanofi | 5 | $137 |
| Haemonetics Corporation | 2 | $132 |
| Amgen | 6 | $123 |
| Insmed, Inc. | 5 | $108 |
| Actelion Pharmaceuticals US, Inc. | 4 | $102 |
| Pfizer | 5 | $89 |
| Viatris Specialty LLC | 3 | $58 |
| Gilead | 2 | $42 |
| Circassia Inc. | 3 | $42 |
| Novartis | 2 | $41 |
| Vifor Pharma, Inc. | 2 | $41 |
| Merck | 2 | $35 |
| Coaptech, Inc. | 1 | $34 |
| Philips North America LLC | 2 | $33 |
| Johnson & Johnson | 1 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Livanova USA, Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,755
- ZEPHYR ENDOBRONCHIAL VALVE$1,088
- AIRSUPRA$224
- TEZSPIRE$224
- FASENRA$224
- Impella$149
- CHARTIS CATHETER$130
- ZEPHYR DELIVERY CATHETER$130
- PULMONX CHARTIS TABLET CONSOLE$130
- Prolastin-C Liquid$120
- Prolastin-C$118
- BREZTRI$111
- OFEV$104
How this compares
$14,458 in reported general payments places this provider in the 90th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $504,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 391 | $297,473 |
| Spiriva RespimatTiotropium Bromide | 218 | $146,862 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 159 | $118,845 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $65,986 |
| NucalaMepolizumab | 17 | $61,013 |
| Incruse ElliptaUmeclidinium Bromide | 135 | $58,828 |
| XolairOmalizumab | 11 | $57,952 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $55,607 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 77 | $54,096 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 330 | $53,277 |
| Arnuity ElliptaFluticasone Furoate | 140 | $31,402 |
| SymbicortBudesonide/Formoterol Fumarate | 96 | $30,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 791 | $25,355 |
| EliquisApixaban | 24 | $21,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $573 | $705,266334 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $952 | $570,310926 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,284 | $157,607273 claims |
| PfizerEliquis | $89 | $21,65524 claims |
| MerckDulera | $35 | $5,47712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Albuquerque
- Lana Melendres GrovesAlbuquerque$1.1M
- Michelle HarkinsAlbuquerque$24K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Sivakumar NagarajuAlbuquerque$5K
- Ronald BronitskyAlbuquerque$4K
- Daniel NazonAlbuquerque$2K
- Sarah MedrekAlbuquerque$2K
- James BradleyAlbuquerque$1K
- Anne BostwickAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.